Q-omics provides the consensus-scored LDB1 profile across patient tissues and cancer cell-line models. LDB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LDB1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, LDB1 RNA expression shows 20,367 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where LDB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDB1 survival associations across molecular data types. LDB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDB1 RNA expression–survival associations across cancer types. High LDB1 expression shows unfavorable associations in READ, but favorable associations in UCS, LGG, UCEC, KIRC and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LDB1 RNA expression.
This table summarizes LDB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LDB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDB1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, LUSC, COAD and CHOL. The HNSC box plot shows higher LDB1 RNA expression in tumor versus normal tissue (log2 FC = +0.958, t-test p < 0.001).
This table shows molecular features associated with LDB1 in patient tissues and cancer cell lines. In patient samples, LDB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LDB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
